Trial clarifies risks of low-dose methotrexate
However, absolute risk is low, say researchers
Low-dose methotrexate can be associated with ‘small to moderate’ elevations in risk for skin cancer and pulmonary, gastrointestinal, haematological and infectious adverse effects (AE), US researchers say.
The investigators from Brigham and Women’s Hospital in Boston, Massachusetts, conducted a prespecified analysis of methotrexate toxicities using data from the Cardiovascular Inflammation Reduction Trial (CIRT).
